436 related articles for article (PubMed ID: 35981346)
21. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
[TBL] [Abstract][Full Text] [Related]
22. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
23. Congenital Conditions of Hypophosphatemia Expressed in Adults.
Marcucci G; Brandi ML
Calcif Tissue Int; 2021 Jan; 108(1):91-103. PubMed ID: 32409880
[TBL] [Abstract][Full Text] [Related]
24. Hypophosphatemic Rickets with R179W Mutation in FGFR23 Gene - A Rare But Treatable Cause of Refractory Rickets.
Sandal S; Arora V; Verma IC
Indian J Pediatr; 2021 Jan; 88(1):61-63. PubMed ID: 32415663
[TBL] [Abstract][Full Text] [Related]
25. Genetic and clinical profile of patients with hypophosphatemic rickets.
Marik B; Bagga A; Sinha A; Khandelwal P; Hari P; Sharma A
Eur J Med Genet; 2022 Aug; 65(8):104540. PubMed ID: 35738466
[TBL] [Abstract][Full Text] [Related]
26. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
27. A PAI-1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D-resistant rickets model mouse.
Qian C; Ito N; Tsuji K; Sato S; Kikuchi K; Yoshii T; Miyata T; Asou Y
FEBS Open Bio; 2024 Feb; 14(2):290-299. PubMed ID: 38050660
[TBL] [Abstract][Full Text] [Related]
28. The pathophysiology of hypophosphatemia.
Ito N; Hidaka N; Kato H
Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101851. PubMed ID: 38087658
[TBL] [Abstract][Full Text] [Related]
29. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
[TBL] [Abstract][Full Text] [Related]
30. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
31. New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia.
Marques JVO; Moreira CA; Borba VZC
Arch Endocrinol Metab; 2022 Nov; 66(5):658-665. PubMed ID: 36382755
[TBL] [Abstract][Full Text] [Related]
32. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
34. [Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism].
Fukumoto S
Rinsho Byori; 2007 Jun; 55(6):555-9. PubMed ID: 17657990
[TBL] [Abstract][Full Text] [Related]
35. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.
Menon LP; Weinstein RS
Bone; 2020 Feb; 131():115137. PubMed ID: 31756522
[TBL] [Abstract][Full Text] [Related]
36. A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome.
Merz LM; Buerger F; Ziegelasch N; Zenker M; Wieland I; Lipek T; Wallborn T; Terliesner N; Prenzel F; Siekmeyer M; Dittrich K
Front Endocrinol (Lausanne); 2022; 13():866831. PubMed ID: 35600592
[TBL] [Abstract][Full Text] [Related]
37. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.
Ito N; Kubota T; Kitanaka S; Fujiwara I; Adachi M; Takeuchi Y; Yamagami H; Kimura T; Shinoda T; Minagawa M; Okazaki R; Ozono K; Seino Y; Fukumoto S
J Bone Miner Metab; 2021 Nov; 39(6):1066-1075. PubMed ID: 34255195
[TBL] [Abstract][Full Text] [Related]
38. [Rickets/Osteomalacia. FGF23-related hypophosphatemic rickets/osteomalacia.].
Fukumoto S
Clin Calcium; 2018; 28(10):1313-1317. PubMed ID: 30269112
[TBL] [Abstract][Full Text] [Related]
39. A New
Terracciano A; De Bernardi ML; Novizio R; De Brasi D; Iolascon A; Monica MD; Scavuzzo F; Serino D; Novelli A; Piscopo C
Endocr Metab Immune Disord Drug Targets; 2023; 23(9):1235-1239. PubMed ID: 36847234
[TBL] [Abstract][Full Text] [Related]
40. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.
Laurent MR; De Schepper J; Trouet D; Godefroid N; Boros E; Heinrichs C; Bravenboer B; Velkeniers B; Lammens J; Harvengt P; Cavalier E; Kaux JF; Lombet J; De Waele K; Verroken C; van Hoeck K; Mortier GR; Levtchenko E; Vande Walle J
Front Endocrinol (Lausanne); 2021; 12():641543. PubMed ID: 33815294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
